ParkinsonCanadaV1, Main, Exploration, bibRecord, 002F38

Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant KOCC and the [18F]fluorodopa plasma input uptake rate constant Ki

Identifieur interne : 002F38 ( Main/Exploration ); précédent : 002F37; suivant : 002F39

Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant KOCC and the [18F]fluorodopa plasma input uptake rate constant Ki

Auteurs : V. Sossi [Canada] ; J. E. Holden [États-Unis] ; R. De La Fuente-Fernandez [Canada] ; T. J. Ruth [Canada] ; A. J. Stoessl [Canada]

Source :

Journal of cerebral blood flow and metabolism [ 0271-678X ] ; 2003.

RBID : Pascal:03-0216455

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dopamine, Stockage, Modèle simulation, Tomographie émission positon, Méthode graphique, Homme, Fluor 18 FDG.
Wicri :
- topic : Stockage, Homme.

English descriptors

KwdEn :
- Adult, Aged, Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (blood), Dihydroxyphenylalanine (metabolism), Dihydroxyphenylalanine (pharmacokinetics), Dopamine, Dopamine (metabolism), Female, Fluorine Radioisotopes, Graphic method, Human, Humans, Male, Middle Aged, Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Parkinson disease, Positron emission tomography, Reference Values, Severity of Illness Index, Simulation model, Storage.
MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , blood : Dihydroxyphenylalanine.
- chemical , metabolism : Dihydroxyphenylalanine, Dopamine.
- chemical , pharmacokinetics : Dihydroxyphenylalanine.
- metabolism : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Adult, Aged, Female, Fluorine Radioisotopes, Humans, Male, Middle Aged, Reference Values, Severity of Illness Index.

Abstract

Parkinson disease is characterized by the loss of dopaminergic neurons, thus decreasing the system's ability to produce and store dopamine (DA). Such ability is often investigated using ¹⁸F-fluorodopa (FD) positron emission tomography. A commonly used model to investigate the DA synthesis and storage rate is the modified Patlak graphical approach. This approach allows for both plasma and tissue input functions, yielding the respective uptake rate constants K_i and K_oc This method requires the presence of an irreversible compartment and the absence of any nontrapped tracer metabolite. In the case of K_occ, this last assumption is violated by the presence of the FD metabolite 3-O-methyl-[¹⁸F]fluoro-dopa (30MFD), which makes the K_occ evaluation susceptible to a downward bias. It was found that both K_i and K_occ are influenced by DA loss and thus are not pure measures of DA synthesis and storage. In the case of K_occ, the presence of 30MFD exacerbates the effect of DA egress, thus introducing a disease-dependent bias in the K_occ determination. These findings imply that K_i and K_occ provide different assessments of disease severity and that, as disease progresses, K_i and especially K_occ become more related to DA storage capacity and less to the DA synthesis rate.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of dopamine loss and the metabolite 3-O-methyl-[<sup>18</sup>
F]fluoro-dopa on the relation between the <sup>18</sup>
F-fluorodopa tissue input uptake rate constant K<sub>OCC</sub>
 and the [<sup>18</sup>
F]fluorodopa plasma input uptake rate constant K<sub>i</sub>
</title>
<author><name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V." last="Sossi">V. Sossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J. E." last="Holden">J. E. Holden</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Wisconsin</s1>
<s2>Madison, Wisconsin</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R." last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of British Columbia/TRIUMF</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia/TRIUMF</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0216455</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0216455 INIST</idno>
<idno type="RBID">Pascal:03-0216455</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B30</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000193</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000958</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000958</idno>
<idno type="wicri:doubleKey">0271-678X:2003:Sossi V:effect:of:dopamine</idno>
<idno type="wicri:Area/Main/Merge">003344</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12621305</idno>
<idno type="wicri:Area/PubMed/Corpus">001449</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001449</idno>
<idno type="wicri:Area/PubMed/Curation">001449</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001449</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001449</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001449</idno>
<idno type="wicri:Area/Ncbi/Merge">000283</idno>
<idno type="wicri:Area/Ncbi/Curation">000283</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000283</idno>
<idno type="wicri:doubleKey">0271-678X:2003:Sossi V:effect:of:dopamine</idno>
<idno type="wicri:Area/Main/Merge">003176</idno>
<idno type="wicri:Area/Main/Curation">002F38</idno>
<idno type="wicri:Area/Main/Exploration">002F38</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of dopamine loss and the metabolite 3-O-methyl-[<sup>18</sup>
F]fluoro-dopa on the relation between the <sup>18</sup>
F-fluorodopa tissue input uptake rate constant K<sub>OCC</sub>
 and the [<sup>18</sup>
F]fluorodopa plasma input uptake rate constant K<sub>i</sub>
</title>
<author><name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V." last="Sossi">V. Sossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J. E." last="Holden">J. E. Holden</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Wisconsin</s1>
<s2>Madison, Wisconsin</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R." last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of British Columbia/TRIUMF</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia/TRIUMF</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of cerebral blood flow and metabolism</title>
<title level="j" type="abbreviated">J. cereb. blood flow metab.</title>
<idno type="ISSN">0271-678X</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of cerebral blood flow and metabolism</title>
<title level="j" type="abbreviated">J. cereb. blood flow metab.</title>
<idno type="ISSN">0271-678X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Dihydroxyphenylalanine (blood)</term>
<term>Dihydroxyphenylalanine (metabolism)</term>
<term>Dihydroxyphenylalanine (pharmacokinetics)</term>
<term>Dopamine</term>
<term>Dopamine (metabolism)</term>
<term>Female</term>
<term>Fluorine Radioisotopes</term>
<term>Graphic method</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Positron emission tomography</term>
<term>Reference Values</term>
<term>Severity of Illness Index</term>
<term>Simulation model</term>
<term>Storage</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dihydroxyphenylalanine</term>
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Fluorine Radioisotopes</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Reference Values</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dopamine</term>
<term>Stockage</term>
<term>Modèle simulation</term>
<term>Tomographie émission positon</term>
<term>Méthode graphique</term>
<term>Homme</term>
<term>Fluor 18 FDG</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Stockage</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson disease is characterized by the loss of dopaminergic neurons, thus decreasing the system's ability to produce and store dopamine (DA). Such ability is often investigated using <sup>18</sup>
F-fluorodopa (FD) positron emission tomography. A commonly used model to investigate the DA synthesis and storage rate is the modified Patlak graphical approach. This approach allows for both plasma and tissue input functions, yielding the respective uptake rate constants K<sub>i</sub>
 and K<sub>oc</sub>
 This method requires the presence of an irreversible compartment and the absence of any nontrapped tracer metabolite. In the case of K<sub>occ</sub>
, this last assumption is violated by the presence of the FD metabolite 3-O-methyl-[<sup>18</sup>
F]fluoro-dopa (30MFD), which makes the K<sub>occ</sub>
 evaluation susceptible to a downward bias. It was found that both K<sub>i</sub>
 and K<sub>occ</sub>
 are influenced by DA loss and thus are not pure measures of DA synthesis and storage. In the case of K<sub>occ</sub>
, the presence of 30MFD exacerbates the effect of DA egress, thus introducing a disease-dependent bias in the K<sub>occ</sub>
 determination. These findings imply that K<sub>i</sub>
 and K<sub>occ</sub>
 provide different assessments of disease severity and that, as disease progresses, K<sub>i</sub>
 and especially K<sub>occ</sub>
 become more related to DA storage capacity and less to the DA synthesis rate.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Wisconsin</li>
</region>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V." last="Sossi">V. Sossi</name>
</noRegion>
<name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R." last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
<name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name>
<name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
</country>
<country name="États-Unis"><region name="Wisconsin"><name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J. E." last="Holden">J. E. Holden</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F38 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F38 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:03-0216455
   |texte=   Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant KOCC and the [18F]fluorodopa plasma input uptake rate constant Ki
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant KOCC and the [18F]fluorodopa plasma input uptake rate constant Ki

Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant KOCC and the [18F]fluorodopa plasma input uptake rate constant Ki

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.